Rivaroxaban Dosing for an 11-Year-Old Child Weighing 24.5 kg
For an 11-year-old child weighing 24.5 kg with venous thromboembolism, rivaroxaban should be dosed at 5 mg twice daily (total daily dose 10 mg), taken with food to ensure adequate absorption. 1, 2
Weight-Based Dosing Algorithm
The FDA-approved pediatric dosing table specifies that children weighing 12 kg to 29.9 kg receive:
Since your patient weighs 24.5 kg, they fall squarely within this weight band and should receive the standard 5 mg twice-daily regimen.
Critical Administration Requirements
Food Requirement
- All doses MUST be taken with food for treatment of VTE in children 2
- Food significantly increases rivaroxaban absorption, ensuring therapeutic drug levels match those of the adult 20 mg daily dose 1, 2
- This is non-negotiable for efficacy 2
Formulation Options
- Either oral suspension or tablets may be used at this weight 1, 2
- If the child cannot swallow whole tablets, use the oral suspension (1 mg rivaroxaban = 1 mL suspension) 2
- Never split tablets to achieve dosing 2
Pre-Treatment Requirements
Mandatory Initial Parenteral Therapy
- Initiate rivaroxaban only after at least 5 days of parenteral anticoagulation (unfractionated heparin or low-molecular-weight heparin) 1, 2
- This initial parenteral phase is required before transitioning to oral rivaroxaban 2
Age and Weight Criteria
For children under 6 months, additional criteria apply (not relevant for your 11-year-old patient):
- Must have been ≥37 weeks gestation at birth
- Must have had ≥10 days of oral feeding
- Must weigh ≥2.6 kg 2
Treatment Duration
Standard VTE Treatment
- Continue therapy for at least 3 months 2
- Treatment may be extended up to 12 months when clinically necessary 2
- Assess the benefit of continued therapy beyond 3 months individually, weighing recurrent thrombosis risk against bleeding risk 2
Exception for Catheter-Related Thrombosis
- For children <2 years old with catheter-related thrombosis, treat for at least 1 month (extendable to 3 months) 2
- This exception does not apply to your 11-year-old patient 2
Monitoring and Dose Adjustments
Weight Monitoring
- Review the dose regularly, especially as the child grows 2
- If weight increases to ≥30 kg, the dose must be increased to 15 mg once daily 1, 2
- If weight drops below 12 kg (unlikely in an 11-year-old), adjust to the appropriate lower weight band 1
Renal Function Considerations
- Mild renal impairment (eGFR 50–80 mL/min/1.73 m²): No dose adjustment needed 2
- Moderate or severe renal impairment (eGFR <50 mL/min/1.73 m²): Avoid rivaroxaban due to limited pediatric data 2
- Calculate eGFR using the updated Schwartz formula if serum creatinine is measured by an enzymatic method traceable to IDMS 2
Guideline Context and Evidence Quality
The 2025 American Society of Hematology/International Society on Thrombosis and Haemostasis guidelines conditionally recommend rivaroxaban over standard-of-care anticoagulants (LMWH, UFH, VKA) for pediatric VTE, based on reduced thrombus recurrence and improved resolution, though with very low certainty of evidence 1. The EINSTEIN-Junior trial demonstrated these benefits, though the panel noted exclusions of children <6 months with low birth weight and those with severe hepatic or renal impairment 1.
Common Pitfalls to Avoid
- Do not use rivaroxaban as initial therapy—always start with parenteral anticoagulation for ≥5 days 2
- Do not administer without food for VTE treatment—this critically reduces absorption 2
- Do not split tablets—use oral suspension if the child cannot swallow whole tablets 2
- Do not forget to reassess dosing as the child grows—crossing the 30 kg threshold requires a dose change 1, 2
- Do not use in moderate-to-severe renal impairment without specialist consultation 2
Vomiting Protocol
If the child vomits or spits up: